With (NYSE: PFE) stock badly underperforming the market over the past three years, falling by 32% while the market rose by close to the same amount, the last thing shareholders want to hear is news of another setback. Alas, the latest stumble was a somewhat unexpected one, and now the company will probably not realize revenue from one of its programs.

But is the stock still worth buying in hopes of a recovery over the long term? To answer that question in more detail, let's put this setback into context.

The story of Pfizer's stock over the last few years is inseparable from the trajectory of its coronavirus vaccine, Comirnaty. In 2022, the vaccine contributed to a total of more than $100 billion in revenue, Pfizer's highest ever. Few thought that such heights were sustainable for the long term, but many, including yours truly, assumed that there would be considerable demand for annual booster doses.

Continue reading

Source Fool.com